Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Total Current Liabilities (2016 - 2025)

Anika Therapeutics (ANIK) has disclosed Total Current Liabilities for 16 consecutive years, with $21.9 million as the latest value for Q4 2025.

  • On a quarterly basis, Total Current Liabilities fell 6.0% to $21.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $21.9 million, a 6.0% decrease, with the full-year FY2025 number at $21.9 million, down 6.0% from a year prior.
  • Total Current Liabilities was $21.9 million for Q4 2025 at Anika Therapeutics, up from $19.1 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $47.0 million in Q1 2021 to a low of $16.1 million in Q2 2025.
  • A 5-year average of $27.4 million and a median of $27.5 million in 2022 define the central range for Total Current Liabilities.
  • Peak YoY movement for Total Current Liabilities: soared 79.37% in 2021, then plummeted 42.54% in 2022.
  • Anika Therapeutics' Total Current Liabilities stood at $29.8 million in 2021, then dropped by 6.31% to $27.9 million in 2022, then rose by 11.27% to $31.1 million in 2023, then dropped by 24.96% to $23.3 million in 2024, then fell by 6.0% to $21.9 million in 2025.
  • Per Business Quant, the three most recent readings for ANIK's Total Current Liabilities are $21.9 million (Q4 2025), $19.1 million (Q3 2025), and $16.1 million (Q2 2025).